NCT02035592

Brief Summary

The purpose of this study is to determine the dose-dependent impact of 6 month freeze-dried blueberry powder intake on insulin sensitivity and resistance, cardiovascular disease risk factors, and lung and cognitive function in overweight and obese participants with metabolic syndrome. We will also examine acute post-prandial effects of blueberry intake (at baseline and at 6-months).

Trial Health

90
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
144

participants targeted

Target at P75+ for not_applicable

Timeline
Completed

Started Jan 2014

Typical duration for not_applicable

Geographic Reach
2 countries

4 active sites

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

January 1, 2014

Completed
9 days until next milestone

First Submitted

Initial submission to the registry

January 10, 2014

Completed
4 days until next milestone

First Posted

Study publicly available on registry

January 14, 2014

Completed
2.8 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

November 7, 2016

Completed
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

November 7, 2016

Completed
Last Updated

September 29, 2017

Status Verified

January 1, 2017

Enrollment Period

2.9 years

First QC Date

January 10, 2014

Last Update Submit

September 28, 2017

Conditions

Outcome Measures

Primary Outcomes (1)

  • Insulin resistance

    Assessed, in the fasted state, via HOMA-IR calculation in all participants; indirect assessment.

    Chronic (0 to 6 month)

Secondary Outcomes (8)

  • Insulin resistance

    Chronic (0 to 6 month)

  • Blood pressure and blood vessel regulation

    Chronic (0 to 6 month)

  • Lung function

    Chronic (0 to 6 month)

  • Cognitive function

    Chronic (0 to 6 month)

  • Liver fat and blood flow assessment

    Chronic (0 to 6 month)

  • +3 more secondary outcomes

Study Arms (3)

Full dose blueberry

ACTIVE COMPARATOR

26g of freeze dried blueberry powder; equivalent to 2 portions of fresh blueberries per day. Frequency: 26g per day. Total duration: 6-month.

Other: Full dose blueberry

Half dose blueberry

ACTIVE COMPARATOR

26g of freeze dried powder; containing 13g of freeze dried blueberry powder and 13g of placebo comparator material; equivalent to 1 portion of fresh blueberries per day. Frequency: 26g per day. Total duration: 6-month.

Other: Half dose blueberry

Control

PLACEBO COMPARATOR

Matched control powder; matched for appearance, taste and sugar content. Frequency: 26g per day. Total duration: 6-month.

Other: Control

Interventions

Full dose: 26g of freeze dried blueberry powder to be incorporated into the habitual diet. Dietary restrictions will be observed (i.e. avoidance of blueberry, and restricted intake of anthocyanin rich foods) for 21 days prior to the first assessment visit and throughout the study.

Full dose blueberry

Half dose: 26g of freeze dried powder (containing 13g of freeze dried blueberry powder and 13g of placebo comparator material) to be incorporated into the habitual diet. Dietary restrictions will be observed (i.e. avoidance of blueberry, and restricted intake of anthocyanin rich foods) for 21 days prior to the first assessment visit and throughout the study.

Half dose blueberry
ControlOTHER

Control: 26g of placebo comparator material to be incorporated into the habitual diet. Dietary restrictions will be observed (i.e. avoidance of blueberry, and restricted intake of anthocyanin rich foods) for 21 days prior to the first assessment visit and throughout the study.

Control

Eligibility Criteria

Age50 Years - 74 Years
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • Men and postmenopausal women (≥ 1 year since last menstruation)
  • to 75 years old
  • BMI of ≥ 25 kg/m2
  • characteristics of metabolic syndrome i.e: Waist circumference ≥ 102 cm for men, ≥ 88 cm for women; Triglycerides ≥ 1.7 mmol/L (or drug treatment for elevated triglycerides); HDL-cholesterol \< 1.0 mmol/L for men, \< 1.3 mmol/L for women (or drug treatment for low HDL-cholesterol); Blood pressure ≥ 130 mm Hg systolic and/or ≥ 85 mm Hg diastolic blood pressure; Fasting blood glucose ≥ 5.56 mmol/L
  • Successful biochemical, haematological and urinalysis assessment at screening

You may not qualify if:

  • Current smokers, or ex-smokers ceasing \< 6 months ago
  • Existing or significant past medical history of vascular disease or medical conditions likely to affect the study measures
  • Fructose intolerance or known allergies to the intervention treatments
  • On therapeutic diets or having experienced substantial weight loss within 3 months of screening
  • Taking flavonoid containing supplements (and unwilling to cease intake during, and 1 month preceding the trial)
  • Planning on altering consumption of vitamin supplements / fish oil capsules during the course of the study.
  • Prescribed hypoglycaemic, vasodilators or HRT medication.
  • Unsatisfactory biochemical, haematological or urinary assessment at screening, or measures considered to be counter indicative for the study
  • \< 3 characteristics of the metabolic syndrome.
  • NB: REC approved NoSA granted to include those on anti-hypertensives (29JUL2014)

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (4)

Harvard School of Public Health

Boston, Massachusetts, 02115, United States

Location

Addenbrooke's hospital

Cambridge, Cambridgeshire, CB2 0QQ, United Kingdom

Location

Norwich Medical School University of East Anglia

Norwich, Norfolk, NR4 7TJ, United Kingdom

Location

Norfolk and Norwich University Hospital

Norwich, Norfolk, NR4 7UY, United Kingdom

Location

Related Publications (3)

  • Curtis PJ, van der Velpen V, Berends L, Jennings A, Haag L, Minihane AM, Chandra P, Kay CD, Rimm EB, Cassidy A. Chronic and postprandial effect of blueberries on cognitive function, alertness, and mood in participants with metabolic syndrome - results from a six-month, double-blind, randomized controlled trial. Am J Clin Nutr. 2024 Mar;119(3):658-668. doi: 10.1016/j.ajcnut.2023.12.006. Epub 2024 Feb 6.

  • Curtis PJ, Berends L, van der Velpen V, Jennings A, Haag L, Chandra P, Kay CD, Rimm EB, Cassidy A. Blueberry anthocyanin intake attenuates the postprandial cardiometabolic effect of an energy-dense food challenge: Results from a double blind, randomized controlled trial in metabolic syndrome participants. Clin Nutr. 2022 Jan;41(1):165-176. doi: 10.1016/j.clnu.2021.11.030. Epub 2021 Nov 27.

  • Curtis PJ, van der Velpen V, Berends L, Jennings A, Feelisch M, Umpleby AM, Evans M, Fernandez BO, Meiss MS, Minnion M, Potter J, Minihane AM, Kay CD, Rimm EB, Cassidy A. Blueberries improve biomarkers of cardiometabolic function in participants with metabolic syndrome-results from a 6-month, double-blind, randomized controlled trial. Am J Clin Nutr. 2019 Jun 1;109(6):1535-1545. doi: 10.1093/ajcn/nqy380.

MeSH Terms

Conditions

Insulin ResistanceMetabolic Syndrome

Condition Hierarchy (Ancestors)

HyperinsulinismGlucose Metabolism DisordersMetabolic DiseasesNutritional and Metabolic Diseases

Study Officials

  • Aedin Cassidy, PhD

    University of East Anglia

    PRINCIPAL INVESTIGATOR

Study Design

Study Type
interventional
Phase
not applicable
Allocation
RANDOMIZED
Masking
QUADRUPLE
Who Masked
PARTICIPANT, CARE PROVIDER, INVESTIGATOR, OUTCOMES ASSESSOR
Purpose
BASIC SCIENCE
Intervention Model
PARALLEL
Sponsor Type
OTHER
Responsible Party
SPONSOR

Study Record Dates

First Submitted

January 10, 2014

First Posted

January 14, 2014

Study Start

January 1, 2014

Primary Completion

November 7, 2016

Study Completion

November 7, 2016

Last Updated

September 29, 2017

Record last verified: 2017-01

Locations